Journal article
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Abstract
BACKGROUND: We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty.
METHODS: In this randomized, double-blind trial, 2531 patients who were to undergo total knee arthroplasty received either oral rivaroxaban, 10 mg once daily, beginning 6 to 8 hours after surgery, or subcutaneous enoxaparin, 40 mg once daily, beginning 12 hours before surgery. The …
Authors
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AGG
Journal
The New England Journal of Medicine, Vol. 358, No. 26, pp. 2776–2786
Publisher
Massachusetts Medical Society
Publication Date
June 26, 2008
DOI
10.1056/nejmoa076016
ISSN
0028-4793